A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865; IND #113912) Followed by Placebo; Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab; in Women With Newly Diagnosed; Previously Untreated; Stage III or IV; Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer